Retatrutide vs Tirzepatide
Retatrutide and tirzepatide are Eli Lilly's two flagship next-generation obesity peptides — built on the same molecular scaffold but with one defining difference. Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, OSA), and the most-prescribed weight-loss drug in the world by 2026. Retatrutide adds a third receptor — glucagon — producing the first triple-agonist obesity drug to reach Phase 3, with TRIUMPH-4 reporting 23.7% mean weight loss in December 2025. This comparison is the honest 'dual vs triple' breakdown, with the trade-offs that the cross-trial weight-loss numbers conceal.
Tirzepatide is the proven, commercially available standard: FDA-approved for type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and obstructive sleep apnea in obesity; head-to-head superiority over semaglutide in SURMOUNT-5 (20.2% vs 13.7%); growing pleiotropic data in cardiovascular, renal, NASH, HFpEF, and OSA endpoints. Retatrutide is the investigational triple agonist with the larger headline weight-loss number — 23.7% at 12 mg in TRIUMPH-4 (December 2025), compared to ~20.9% for tirzepatide at 72 weeks — produced by adding glucagon-receptor agonism to drive hepatic fat oxidation and thermogenesis on top of the dual GIP/GLP-1 appetite suppression. The honest caveats on the cross-trial advantage are real: no head-to-head trial has been completed, retatrutide carries a modest resting heart-rate increase (+2–6 bpm) and uncharacterized long-term safety, and it is not yet FDA-approved (anticipated late 2026 or 2027). For most patients today the choice is straightforward — tirzepatide is the option that actually exists in the pharmacy. Retatrutide will be the consequential decision once it's approved, especially in patients where the extra ~3–5 percentage points of weight loss or the glucagon-driven liver-fat reduction matters more than the additional safety and tolerability data tirzepatide has accumulated.
Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.
Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
| Category | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor Mechanism | Triple agonist — GIP + GLP-1 + glucagon | Dual agonist — GIP + GLP-1 |
| Molecule | 39-amino-acid synthetic peptide (LY3437943) with C-20 fatty diacid for albumin binding | 39-amino-acid synthetic peptide (LY3298176) with C-20 fatty diacid for albumin binding |
| Sponsor | Eli Lilly (investigational) | Eli Lilly (commercial — Mounjaro / Zepbound) |
| FDA Status | Not approved. Phase 3 TRIUMPH program in progress; regulatory filing signaled for 2026, anticipated approval late 2026 or 2027. | FDA-approved as Mounjaro (T2D, May 2022) and Zepbound (chronic weight management, November 2023; obstructive sleep apnea in obesity, December 2024). |
| Headline Weight Loss | 23.7% mean at 12 mg over Phase 3 TRIUMPH-4 (December 2025); 24.2% at 12 mg over 48 weeks in Phase 2 NEJM 2023 (Jastreboff et al.) — the largest obesity-drug weight loss ever recorded at that time | 20.9% at 15 mg over 72 weeks in SURMOUNT-1 (Phase 3); 20.2% over 72 weeks in SURMOUNT-5 head-to-head vs semaglutide (13.7%) |
| Direct Head-to-Head Trial | None completed. All retatrutide-vs-tirzepatide comparisons are cross-trial. | Same — no published RCT directly comparing the two molecules. A head-to-head would be the most consequential next trial in the field. |
| Type 2 Diabetes Outcomes (HbA1c) | Up to -2.02% at 12 mg over 36 weeks (Phase 2, Rosenstock 2023). HbA1c suppression dose-comparable to tirzepatide, with a noted glucagon-driven transient excursion at the highest doses early in titration. | -2.0 to -2.4% across SURPASS-1 through SURPASS-5 in T2D; superior to semaglutide 1 mg in SURPASS-2 (-2.30% vs -1.86%) |
| MASH / Liver Fat | >80% relative liver-fat reduction at 48 weeks in Phase 2a MASLD (Sanyal 2024); substantial proportion achieved complete MASH resolution. Glucagon-driven hepatic fat oxidation is the mechanistic differentiator here. | SYNERGY-NASH Phase 2 showed superior fibrosis improvement and MASH resolution versus placebo; effective but without the glucagon-receptor liver-fat oxidation that retatrutide adds |
| OSA | Phase 3 TRIUMPH program includes a dedicated OSA arm; results not yet published | FDA-approved December 2024 for moderate-to-severe OSA in adults with obesity, on the strength of SURMOUNT-OSA Phase 3 data |
| Cardiovascular Outcomes | TRIUMPH-Outcomes CVOT enrolling; no published mortality or MACE data | SURPASS-CVOT exploratory analysis (2026, Lancet Diab Endo) showed 23% reduction in major kidney events vs dulaglutide; rigorous CV safety meta-analysis confirmed no increased mortality. Full CV outcome trial pending. |
| Body Composition | Phase 2 substudy (Conte 2025, Lancet Diabetes Endo): proportional fat-mass loss preserved, with broadly similar lean-vs-fat ratios to tirzepatide; longer-term Phase 3 body-composition data not yet published | SURMOUNT-1 body-composition data: lean mass typically 25–40% of total weight loss, with the remainder fat mass; ratio broadly comparable to other major weight-loss interventions |
| Maintenance Strategy | No published withdrawal or dose-reduction data. Assumption is similar weight regain after stopping, awaiting confirmation. | SURMOUNT-MAINTAIN (2026, Lancet): a 5 mg maintenance dose after the maximum tolerated dose preserved -16.6% from baseline at 112 weeks, versus -9.9% on placebo and -21.9% continuing the MTD. Dose reduction works; stopping doesn't. |
| Dosing | Once-weekly SC. Phase 2 used 1, 4, 8, 12 mg; Phase 3 TRIUMPH uses 4, 8, 12 mg maintenance after 2→4→8→12 mg titration at 4-week intervals | Once-weekly SC. 2.5 mg starting dose, titrated through 5, 7.5, 10, 12.5, and 15 mg at 4-week intervals as tolerated |
| GI Tolerability | Class-typical incretin GI profile — nausea, vomiting, diarrhea, constipation concentrated at titration. Magnitude broadly comparable to tirzepatide at matched titration steps in Phase 2. | Class-typical — nausea (~30% at the higher maintenance doses), vomiting, diarrhea, constipation. Generally well-managed with slow titration and dietary adjustment. |
| Cardiac Effects (Beyond MACE) | Modest resting heart-rate elevation (+2–6 bpm at higher doses) attributable to the glucagon-receptor component; magnitude comparable to other glucagon-containing agonists. No QTc signal observed in Phase 2. | Modest resting heart-rate elevation (+2–4 bpm at higher doses) — class effect of GLP-1 agonism. Not associated with increased arrhythmia or MACE in completed trials. |
| Glycemic Profile Caveat | The glucagon-receptor component can produce transient HbA1c excursions or modest hyperglycemia in early titration — actively monitored in Phase 3. Net glycemic effect at maintenance dose is strongly favorable. | Predictably glucose-lowering across the dose range; no glucagon-component excursions. The cleaner glycemic profile is one reason tirzepatide reached T2D approval first. |
| Pricing (List, US) | N/A — not commercially available | ~$1,060/month Zepbound list price (Lilly Direct); ~$1,090/month Mounjaro list. Insurance coverage and rebates vary substantially. |
| Compounding Status | Not a legal 503A compounding product — no FDA-approved reference product, no validated bulk drug substance list entry. Grey-market vendors notwithstanding. | FDA-resolved off the drug-shortage list in 2024; commercial compounding pathway is now narrow/closed. Patient access is through the branded product. |
| Sports / WADA Status | Not named on WADA Prohibited List, but WADA S0 captures unapproved investigational substances. Athletes should treat as prohibited. | Not currently on the WADA Prohibited List, but increasingly scrutinized as performance-relevant in body-composition-sensitive sports. TUE pathway under discussion. |
| Defining Differentiator | The added glucagon receptor — drives extra hepatic fat oxidation, energy expenditure, and the highest weight-loss numbers reported in obesity pharmacotherapy. Trade-off is uncharacterized long-term safety and an extra mechanistic axis to monitor (HR, glycemic excursions). | Maturity and breadth of evidence — FDA approval across three obesity-adjacent indications (T2D, weight management, OSA), head-to-head superiority over semaglutide, published maintenance-dose data, growing pleiotropic outcomes in CV, renal, NASH, HFpEF, and psoriasis trials. |
In depth
The same molecule, plus one receptor
Tirzepatide and retatrutide are sister molecules. Both are 39-amino-acid synthetic peptides from Eli Lilly. Both carry a C-20 fatty diacid for albumin binding and weekly dosing. Both activate GIP and GLP-1 receptors centrally to suppress appetite. The defining difference is one extra receptor — retatrutide adds glucagon agonism, which drives hepatic fat oxidation, increases energy expenditure, and produces the largest weight-loss numbers ever reported in obesity pharmacotherapy. That one mechanistic addition is the entire story. In cross-trial comparisons, retatrutide at the 12 mg dose has produced 23.7–24.2% mean weight loss (Phase 3 TRIUMPH-4 in December 2025, and the Phase 2 NEJM trial in 2023), while tirzepatide at the 15 mg dose has produced 20.9% in SURMOUNT-1 (Phase 3) and 20.2% in SURMOUNT-5 versus semaglutide. The headline retatrutide advantage is real but should be read with two important caveats: no head-to-head trial has been completed, and tirzepatide's data is at 72 weeks while retatrutide's Phase 2 was at 48 weeks (with the weight-loss curve still sloping downward at trial end, suggesting the gap might narrow with longer exposure on tirzepatide and widen further with longer exposure on retatrutide). The honest position today is that retatrutide appears mechanistically and quantitatively to produce more weight loss than tirzepatide, but the magnitude of that advantage in a true head-to-head trial is unknown.
Why glucagon matters mechanistically
The argument for adding glucagon-receptor activation to dual GIP/GLP-1 agonism is straightforward: GLP-1 and GIP reduce calorie intake by suppressing appetite, but they don't change the energy-expenditure side of the equation. Glucagon does. Glucagon-receptor activation increases hepatic fat oxidation, elevates resting energy expenditure, and drives thermogenesis. The classical problem with glucagon — its hyperglycemic effect — is offset by the glucose-lowering action of the GLP-1 and GIP components, so the net glycemic effect of the triple agonist is still strongly favorable (Phase 2 HbA1c reduction up to -2.02%). The 2026 metabolomics substudy (Pearson et al., n=495) provided the first mechanistic decomposition of retatrutide's weight-loss signature in humans. Higher doses drove a coordinated increase in fatty-acid oxidation markers (3-hydroxybutyrate, acetylcarnitine, free carnitine, long-chain acylcarnitines) plus reductions in insulin-resistance markers (branched-chain amino acids, 2-aminoadipic acid, urate). Mediation analysis attributed approximately 23.2% of the weight-reduction effect in non-T2D participants to the acylcarnitine cluster alone — direct human evidence that the glucagon-receptor-driven fatty-acid oxidation pathway is a meaningful contributor to retatrutide's weight loss, not just a pharmacological hypothesis.
Liver fat: where retatrutide's mechanistic story shines hardest
If weight loss is where retatrutide's advantage is real but contested, liver fat is where the mechanistic case is strongest. The Phase 2a MASLD trial (Sanyal et al., NEJM 2024) reported greater than 80% relative liver-fat reduction at 48 weeks, with a substantial proportion of participants achieving complete MASH resolution. Tirzepatide's SYNERGY-NASH Phase 2 program also showed meaningful fibrosis improvement and MASH resolution, but the magnitude of the liver-fat effect was notably smaller, consistent with the absence of direct glucagon-receptor stimulation in tirzepatide. For patients whose primary cardiometabolic problem is hepatic steatosis or MASH rather than (or in addition to) weight, the retatrutide profile is mechanistically the more aligned one.
Where tirzepatide's mature evidence base is the bigger asset
For most actual prescribing decisions today, the question is not which molecule has the bigger headline number — it's which one has the evidence base, the regulatory approval, and the access pathway. Tirzepatide wins all three by a wide margin. It is FDA-approved for type 2 diabetes (Mounjaro, May 2022), chronic weight management (Zepbound, November 2023), and obstructive sleep apnea in adults with obesity (Zepbound, December 2024). It has a completed head-to-head superiority trial against semaglutide (SURMOUNT-5: 20.2% vs 13.7%). It has growing pleiotropic data — a 23% reduction in major kidney events in SURPASS-CVOT's exploratory analysis (Lancet Diab Endo 2026), significant improvements in HFpEF symptoms and exercise capacity in a dedicated trial, superior fibrosis improvement in MASH, and a 2026 Phase 3b trial in psoriasis with obesity that quintupled simultaneous skin-clearance and weight-loss rates versus ixekizumab alone. It has SURMOUNT-MAINTAIN (Lancet 2026), the trial that established 5 mg as a viable maintenance dose for preserving weight loss after the maximum tolerated dose. And it has approximately four years of post-marketing real-world safety data that retatrutide will need years more to accumulate. Retatrutide's Phase 3 TRIUMPH program is doing the right work — seven trials covering obesity, type 2 diabetes, OSA, hypertension, NASH, and a dedicated cardiovascular outcomes trial — but those readouts will be unfolding over 2026–2028. As of mid-2026, the only obesity-relevant Phase 3 readout for retatrutide is TRIUMPH-4 (December 2025).
Safety and tolerability: similar enough, but the heart rate matters
The GI tolerability profiles of retatrutide and tirzepatide at matched titration steps in published Phase 2 data are broadly comparable — class-typical nausea, vomiting, diarrhea, and constipation concentrating at dose-escalation transitions and improving with maintenance. Slow titration manages most of this, and the discontinuation rates in retatrutide Phase 2 were not meaningfully different from tirzepatide Phase 2 at matched doses. The meaningful tolerability difference is the heart rate. Both molecules raise resting heart rate modestly through GLP-1-class effects; retatrutide raises it slightly more (+2–6 bpm at higher doses vs +2–4 bpm for tirzepatide) because the glucagon-receptor component independently contributes a small thermogenic and chronotropic effect. In completed Phase 2 trials this has not translated into a safety signal — no arrhythmia or MACE increase — but it is one of the things Phase 3 TRIUMPH is designed to characterize across longer exposure and broader populations. The other glucagon-component watchpoint is the transient HbA1c excursion that can occur in early titration before the GLP-1/GIP glucose-lowering effects fully offset glucagon's hyperglycemic action; this is manageable with titration protocols and has not translated into adverse glycemic outcomes in trials.
Access and cost
For the patient asking which one they should be on today, the answer is currently structural rather than mechanistic. Tirzepatide is commercially available at major US pharmacies as Mounjaro (T2D indication) or Zepbound (obesity / OSA indication), with list price around $1,000–1,100 per month before insurance, and a growing array of Lilly Direct cash-pay programs, savings cards, and insurance coverage pathways. Retatrutide is available only through enrollment in Lilly's TRIUMPH clinical trial sites, and is not legally available through compounding (no approved reference product, no validated bulk drug substance entry). Grey-market and research-chemical vendors advertise retatrutide, but those products carry unresolved regulatory and quality concerns, and the typical product-quality variance in that channel is real. The Lilly business question — when retatrutide is approved, how Lilly positions it relative to existing Zepbound — is interesting but speculative. The likely commercial trajectory is that retatrutide enters the market at a higher list price aimed at the high-magnitude-weight-loss segment, with Zepbound holding the mid-tier obesity space, similar to the semaglutide/tirzepatide pricing dynamic today. Patients on Zepbound today are not strictly losing optionality by waiting for retatrutide — both molecules will likely coexist as Lilly's obesity portfolio.
How to choose
If you're choosing today: tirzepatide is the answer for essentially everyone, because retatrutide isn't approved and isn't legally accessible outside trials. If you're choosing once retatrutide is approved: the calculus shifts to which mechanism aligns with the dominant clinical problem. For weight loss alone, retatrutide's roughly 3–5 percentage-point advantage is real but modest at the population level (and the head-to-head magnitude is unknown). For weight loss plus hepatic steatosis or MASH, retatrutide's glucagon-driven liver-fat oxidation is a mechanistically larger advantage. For weight loss plus established type 2 diabetes, both are highly effective; tirzepatide has the longer track record and the cleaner glycemic profile, retatrutide has the larger absolute HbA1c numbers in Phase 2. For weight loss plus OSA, tirzepatide is the labeled choice today; retatrutide's TRIUMPH-OSA arm has not reported. For patients with significant pre-existing tachycardia or atrial fibrillation, tirzepatide's smaller heart-rate footprint may be preferable.
Bottom line
Retatrutide is the more potent molecule on weight loss and liver fat. Tirzepatide is the mature molecule on regulatory approval, real-world evidence, pleiotropic indications, and maintenance-dose data. Today the choice is forced — tirzepatide is the only one that exists in the pharmacy. Once retatrutide is approved (anticipated late 2026 or 2027), the choice will turn on whether the extra mechanistic firepower of glucagon-receptor agonism matches the patient's dominant cardiometabolic problem, whether the modest extra heart-rate cost is acceptable, and whether the depth of long-term safety data justifies waiting another year or two for the post-marketing record to mature. For the average patient with obesity alone, tirzepatide is likely to remain the default for most of 2027–2028; retatrutide will be the consequential choice in the subset where weight-loss magnitude or hepatic-fat reduction is the dominant clinical priority.
These peptides are often used together. See our stack profiles for combination details.